Effect of ZILRETTA Versus CELESTONE on Quality of Life, Pain, Neuromuscular Function, and Physical Performance

The purpose of this study is to examine the pre, post, and follow up effects of a single ZILRETTA knee injection vs a single CELESTONE SOLUSPAN knee injection on physiological measure of self-reported quality of life, pain, physical function, and physical performance in individuals with osteoarthritis (OA) knee pain. The Primary Investigator (PI) will recruit 20 symptomatic knee OA patients for this study. Patients will be randomized into one of two treatment arms, Arm 1 (ZILRETTA injection) or Arm 2 (CELESTONE SOLUSPAN injection). Patients in Arm 1 will receive a single 5 mL IV injection of 32 mg ZILRETTA into the affected knee joint. Patients in Arm 2 will receive a 5ml IV injection of 6mg/ml CELESTONE SOLUSPAN into the affected knee joint. Each study arm will include 10 patients. All data will be collected prior to injection (baseline), as well as at 6-week (post 1) and 12-week follow-ups (post 2). Patients will blinded to treatment arm until after they complete their 12-week follow up.

Study Overview

• Status: Completed
• Conditions: Osteoarthritis, Knee
• Intervention / Treatment: Drug: Triamcinolone acetonide extended-release injectable suspension; Drug: Betamethasone sodium phosphate and betamethasone acetate Injectable Suspension

Detailed Description

Individuals with knee osteoarthritis (OA) often experience pain and difficulty completing many everyday activities, such as walking or climbing stairs. It is a major cause of lost work time and a serious disability for many people. Although there is no cure for arthritis, there are many treatment options available to help manage pain and keep people active.

The ZILRETTA knee injection and CELESTONE knee injection are both FDA approved, extended-release corticosteroid, and are both common nonsurgical treatment options for patients with OA. Currently, there are no studies that have compared ZILRETTA and CELESTONE SOLUSPAN.

c. Aims Specific Aim 1: To determine the difference between intra-articular (IA) injection of Zilretta and intra-articular injection of Celestone in patients with knee OA improves physical performance (OARSI recommended physical performance measures).

Primary Hypothesis 1: Patients who receive knee IA injection of Zilretta or Celestone experience improved physical performance detectable at 6 weeks and 12 weeks.

Specific Aim 2: To determine the difference between IA injection of Zilretta and IA injection of Celestone in patients with knee OA improves physical function (KOOS-PF).

Hypothesis 2: Patients who receive knee IA injection of Zilretta or Celestone report improved patient-reported physical function (KOOS-PS) at 6 weeks and 12 weeks.

Specific Aim 3: To determine the difference between knee IA injection of Zilretta or Celestone in patients with knee OA improves quality of life (KOOS-QoL).

Hypothesis 3: Patients who receive knee IA injection of Zilretta or Celestone report improved quality of life (KOOS-QoL) detectable at 6 weeks and 12 weeks.

Specific Aim 4: To determine the difference between knee IA injection of Zilretta or Celestone in patients with knee OA improves pain based on numeric pain rating scale.

Hypothesis 3: Patients who receive knee IA injection of Zilretta or Celestone report improved pain level detectable at 6 weeks and 12 weeks.

II. Research Plan and Design

1. Study Objective The goal of this study is to evaluate the efficacy of Zilretta compared to Celestone for improving quality of life, pain, neuromuscular function, and physical performance.
2. Study Design The proposed study will compare Zilretta and Celestone effectiveness on patient-reported outcomes (quality of life, neuromuscular functioning, and pain) and physical performance (30-second chair standing test, 40m fast-paced walking test, stair ascent) related to knee arthritis. Patients will be chosen based on the level of arthritis of the knee and interest in non-surgical treatment options. After informed consent but before injection, Patients will be randomized into Zilretta or Celestone treatment arms. Patients will be consented and seen at baseline, in clinic at 6-weeks, and phone call follow-up at 12-weeks. Demographic information as well as any comorbidity or adverse events related to poor healing will be recorded.

Baseline

After completing informed consent but prior to injection, patients will complete:

• OARSI recommended physical performance tests (30-second chair standing test, 40m fast-paced walking test, stair ascent)
• KOOS-PS (Physical Function Shortform) - 7 questions
• KOOS-Quality of life subscale (QoL) - 4 questions
• Numerical Rating Scale (NRS) 6-week (Post 1)

During the 6-week follow up visit with the PI, patients will complete:

• OARSI recommended physical performance tests (30-second chair standing test, 40m fast-paced walking test, stair ascent) 12 weeks after treatment
• KOOS-PS (Physical Function Shortform) - 7 questions
• KOOS-Quality of life subscale (QoL) - 4 questions
• Numerical Rating Scale (NRS) 12-week (Post 2)

At 12-weeks post-injection, the Clinical Research Coordinator (CCRC) or Research Assistant (RA) will call each patient and patients will complete:

• KOOS-PS (Physical Function Shortform) - 7 questions
• KOOS-Quality of life subscale (QoL) - 4 questions
• Numerical Rating Scale (NRS)

If patients indicate any adverse events, high levels of pain, or have medical questions, the CCRC or RA will schedule the patient to be seen by the PI.

• Study Type: Interventional
• Enrollment (Actual): 20
• Phase: Phase 4

Contacts and Locations

Study Locations

• United States
  • Nevada
    • Reno, Nevada, United States, 89503
      • Reno Orthopedic Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria

• Men and women age 18 years or older with symptomatic bilateral knee OA
• Symptomatic knee OA will be defined as the presence of a definite osteophyte or joint space narrowing (KL Grade ≥2) on posteroanterior (PA) fixed flexion knee radiographs in subjects limited by bilateral pain rated on a Numerical Rating Scale as ≥ 4/10 on more than half of the days over the past month. Radiographic change must be visible at standard image size, irrespective of capability to detect more subtle changes through digital enhancement.
• Bilateral knee symptoms for ≥ 3 months prior to screening
• Has undergone at least one prior conservative osteoarthritis treatment (e.g. Physical therapy, analgesics)
• Ambulatory
• Willing and able to comply with the study procedures and visit schedules and ability to follow verbal and written instructions.

Exclusion Criteria

• Current consumption of more than 14 alcoholic drinks per week
• Clinical signs and symptoms of active knee infection or crystal disease of either knee within 1 month of screening
• Diagnosed with rheumatoid arthritis, Reiter's syndrome, psoriatic arthritis, gout, ankylosing spondylitis, or arthritis secondary to other inflammatory diseases; HIV, viral hepatitis; chondrocalcinosis, Paget's disease, or villonodular synovitis
• Diagnosed with leukemia, known presence of metastatic malignant cells, or ongoing or planned chemotherapeutic treatment.
• A gout attack in the past 2 years.
• Diseases of the spine, hip or other lower extremity joints judged by the investigator to be contributing to the pain in either knee (i.e. sciatica, nerve pain, hip OA). Note: Patients with hip replacement in either hip may be enrolled provided there is sufficient pain relief after hip replacement that analgesics are not required.
• Untreated symptomatic injury of either knee (e.g., acute traumatic injury, anterior cruciate ligament injury, clinically symptomatic meniscus injury characterized by a mechanical issue such as locking or catching).
• Uncontrolled diabetes (HbA1c >7.2)
• Women who report pregnancy or childbearing potential and not using acceptable contraceptive measures (oral contraceptive, long acting reversible contraceptive therapy) (due to the potential for change in body mass and distribution to alter knee symptoms over the period of follow-up).
• Presence of surgical hardware or other foreign body intended to treat arthritis or cartilage-related pathology in either knee.
• Arthroscopy or open surgery of either knee within 6 months of screening.
• Planned/anticipated surgery of either knee during the study period.
• Use of systemic immunosuppressant within 6 weeks of screening.
• Oral corticosteroids (investigational or marketed) within 2 weeks of screening (unless on chronic stable dose for >3 months).
• IA corticosteroid (investigational or marketed) in either knee within 3 months of screening.
• IV or IM (Intramuscular) Corticosteroid injection (investigational or marketed) within 3 months of screening.
• Any other IA drug/biologic use within 6 months of screening or 5 half-lives (whichever is longer) (e.g., hyaluronic acid, platelet-rich plasma (PRP) injection, stem cells, prolotherapy and amniotic fluid injection).
• Any documented clinically significant degree of cognitive impairment or other condition, finding, or psychiatric illness at screening which, in the opinion of the investigator, could compromise subject safety.
• Any condition other than OA of the knee which, in the opinion of the investigator, affects the ability to ambulate to a sufficient degree to interfere with the assessment of the safety and treatment effects of the study injection.
• Participated in any interventional drug or device trial within 30 days prior to screening or concurrent participation in another research study that could complicate interpretation of the study findings.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Arm 1; Triamcinolone acetonide extended-release injectable suspension. Single intra-articular extended-release injection of triamcinolone acetonide, to deliver 32 mg (5 mL). For intra-articular use only and should not be administered by the following routes: epidural, intrathecal, intravenous, intraocular, intramuscular, intradermal, subcutaneous.	Drug: Triamcinolone acetonide extended-release injectable suspension; Zilretta (Triamcinolone acetonide extended-release injectable suspension) is indicated as an intra-articular injection for the management of pain due to knee OA. The most commonly reported adverse reactions (incidence ≥1%) in clinical studies included sinusitis (2%), cough (2%), contusions (2%) and joint swelling (3%). For additional details, please see Package Insert (http://www.zilrettalabel.com/PI.pdf). The website for Zilretta additionally lists: joint pain, headache, back pain, sore throat and runny nose, and bruising as common side effects of receiving a Zilretta injection.; Other Names: Zilretta
Active Comparator: Arm 2; Betamethasone sodium phosphate and betamethasone acetate Injectable Suspension, USP 6 mg per mL, 3 mg per milliliter betamethasone, as betamethasone sodium phosphate, and 3 mg per milliliter betamethasone acetate. When oral therapy is not feasible, the Injectable Suspension is indicated for intramuscular use only.	Drug: Betamethasone sodium phosphate and betamethasone acetate Injectable Suspension; Celestone (betamethasone sodium phosphate and betamethasone acetate Injectable Suspension, USP 6 mg per mL) is indicated as an intra-articular injection for the management of chronic or long-term inflammation associated with multiple conditions including severe allergies, dermatological diseases, endocrine disorders, gastrointestinal diseases, hematologic disorders, neoplastic diseases, nervous system disorders, ophthalmologic diseases, renal diseases, respiratory diseases and rheumatic disorders, and others that may not be listed. Celestone Soluspan is available in generic form. The most commonly reported adverse reactions include acne, increased hunger, and weight gain.; Other Names: Celestone

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
OARSI - 30-second Chair Stand	The maximum number of chair stand repetitions possible in a 30 second period (2-4).	Baseline (removed due to COVID)
OARSI - 30-second Chair Stand	The maximum number of chair stand repetitions possible in a 30 second period (2-4).	6 week (removed due to COVID)
OARSI - 30-second chair standing test	The maximum number of chair stand repetitions possible in a 30 second period (2-4).	12 week (removed due to COVID)
OARSI - 40m Fast Paced Walk	A fast-paced walking test that is timed over 4 x 10m (33 ft) for a total 40 m (132 ft) (2).	Baseline (removed due to COVID)
OARSI - 40m Fast Paced Walk	A fast-paced walking test that is timed over 4 x 10m (33 ft) for a total 40 m (132 ft) (2).	6 week (removed due to COVID)
OARSI - 40m Fast Paced Walk	A fast-paced walking test that is timed over 4 x 10m (33 ft) for a total 40 m (132 ft) (2).	12 week (removed due to COVID)
OARSI - stair ascent	The time (in seconds) it takes to ascend and descend a flight of stairs (2-6). The number of stairs will depend on individual environmental situations. Where possible, the 9-step stair test with 20cm (8 inch) step height and handrail is recommended.	Baseline (removed due to COVID)
OARSI - stair ascent	The time (in seconds) it takes to ascend and descend a flight of stairs (2-6). The number of stairs will depend on individual environmental situations. Where possible, the 9-step stair test with 20cm (8 inch) step height and handrail is recommended.	6 week (removed due to COVID)
OARSI - stair ascent	The time (in seconds) it takes to ascend and descend a flight of stairs (2-6). The number of stairs will depend on individual environmental situations. Where possible, the 9-step stair test with 20cm (8 inch) step height and handrail is recommended.	12 week (removed due to COVID)
KOOS-PS (Physical Function Shortform)	Scoring: Never/none=0, Monthly/mild=1, Weekly/moderate=2, Daily/severe=3, Always/extreme=4. Calculate the mean score for the 11 items, and divide by the maximum possible score for each item (i.e. 4). Traditionally in orthopedics, 100 indicates no problems and 0 indicates extreme problems. The normalized score is transformed to meet this standard. Please use the formula provided below. 100 - [(mean score PF1-PF11)/4 *100]	6 week
KOOS-PS (Physical Function Shortform)	Scoring: Never/none=0, Monthly/mild=1, Weekly/moderate=2, Daily/severe=3, Always/extreme=4. Calculate the mean score for the 11 items, and divide by the maximum possible score for each item (i.e. 4). Traditionally in orthopedics, 100 indicates no problems and 0 indicates extreme problems. The normalized score is transformed to meet this standard. Please use the formula provided below. 100 - [(mean score PF1-PF11)/4 *100]	Baseline
KOOS-PS (Physical Function Shortform)	Scoring: Never/none=0, Monthly/mild=1, Weekly/moderate=2, Daily/severe=3, Always/extreme=4. Calculate the mean score for the 11 items, and divide by the maximum possible score for each item (i.e. 4). Traditionally in orthopedics, 100 indicates no problems and 0 indicates extreme problems. The normalized score is transformed to meet this standard. Please use the formula provided below. 100 - [(mean score PF1-PF11)/4 *100]	12 week
KOOS-Quality of life subscale (QoL)	The KOOS's five patient-relevant dimensions are scored separately: Pain (nine items); Symptoms (seven items); ADL Function (17 items); Sport and Recreation Function (five items); Quality of Life (four items). A Likert scale is used and all items have five possible answer options scored from 0 (No problems) to 4 (Extreme problems) and each of the five scores is calculated as the sum of the items included. Scores are transformed to a 0-100 scale, with zero representing extreme knee problems and 100 representing no knee problems as common in orthopaedic scales and generic measures. Scores between 0 and 100 represent the percentage of total possible score achieved.	Baseline
KOOS-Quality of life subscale (QoL)	The KOOS's five patient-relevant dimensions are scored separately: Pain (nine items); Symptoms (seven items); ADL Function (17 items); Sport and Recreation Function (five items); Quality of Life (four items). A Likert scale is used and all items have five possible answer options scored from 0 (No problems) to 4 (Extreme problems) and each of the five scores is calculated as the sum of the items included. Scores are transformed to a 0-100 scale, with zero representing extreme knee problems and 100 representing no knee problems as common in orthopaedic scales and generic measures. Scores between 0 and 100 represent the percentage of total possible score achieved.	6 week
KOOS-Quality of life subscale (QoL)	The KOOS's five patient-relevant dimensions are scored separately: Pain (nine items); Symptoms (seven items); ADL Function (17 items); Sport and Recreation Function (five items); Quality of Life (four items). A Likert scale is used and all items have five possible answer options scored from 0 (No problems) to 4 (Extreme problems) and each of the five scores is calculated as the sum of the items included. Scores are transformed to a 0-100 scale, with zero representing extreme knee problems and 100 representing no knee problems as common in orthopaedic scales and generic measures. Scores between 0 and 100 represent the percentage of total possible score achieved.	12 week
Numerical Rating Scale (NRS)	patient to rate their pain on a defined scale. For example, 0-10 where 0 is no pain and 10 is the worst pain imaginable	Baseline
Numerical Rating Scale (NRS)	patient to rate their pain on a defined scale. For example, 0-10 where 0 is no pain and 10 is the worst pain imaginable	6 week
Numerical Rating Scale (NRS)	patient to rate their pain on a defined scale. For example, 0-10 where 0 is no pain and 10 is the worst pain imaginable	12 week

Collaborators and Investigators

• Sponsor: ROC Foundation
• Investigators: Study Director: Sara C DePaoli, ROC Foundation; Principal Investigator: Timothy J Bray, MD, ROC Foundation

Study record dates

Study Major Dates

• Study Start (Actual): November 30, 2020
• Primary Completion (Actual): April 28, 2021
• Study Completion (Actual): April 28, 2021

Study Registration Dates

• First Submitted: September 7, 2021
• First Submitted That Met QC Criteria: September 17, 2021
• First Posted (Actual): September 27, 2021

Study Record Updates

• Last Update Posted (Actual): September 27, 2021
• Last Update Submitted That Met QC Criteria: September 17, 2021
• Last Verified: September 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Arthritis; Osteoarthritis; Osteoarthritis, Knee; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Anti-Inflammatory Agents; Immunosuppressive Agents; Immunologic Factors; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Anti-Asthmatic Agents; Respiratory System Agents; Betamethasone; Betamethasone Valerate; Betamethasone-17,21-dipropionate; Betamethasone benzoate; Betamethasone sodium phosphate; Triamcinolone; Triamcinolone Acetonide; Triamcinolone hexacetonide; Triamcinolone diacetate; Betamethasone acetate
• Other Study ID Numbers: 1657878

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No